Dr Nicholas Short speaks to ecancer about a study he presented at the virtual ASH 2020 meeting on the use of hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL.
He reports that all patients in the study achieved a complete response and 97% of patients achieved MRD negativity.
Dr Short hopes that these kind of regimens can lead to a transplant-free minimal chemotherapy regimen in the front line setting.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.